| Ytd | 380.65% | |
| 1y | 1038.85% |
| Open | 17.87 | Prev Close | 18.03 | Low | 17.17 | High | 18.03 | Mkt Cap | 6.25B |
| Vol | 4.77M | Avg Vol | 4.78M | EPS | -0.95 | P/E | N/A | Forward P/E | -29.94 |
| Beta | 0.65 | Short Ratio | 7.32 | Inst. Own | 85.77% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 18.10 | 200-d Avg | 12.49 | 1yr Est | 24.30 |
ERAS News
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recogn
BlackRock Inc. acquired a new position in Erasca, Inc. (NASDAQ: ERAS) in the second quarter, accordi
The Alger Mid Cap 40 ETF outperformed the Russell Midcap Growth Index during the second quarter of 2
Designation follows encouraging Phase 1 activity across multiple tumor types including 2L+ KRAS G12X
New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recogn
Handelsbanken Fonder AB bought a new position in shares of Erasca, Inc. (NASDAQ: ERAS) during the se
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises
Guggenheim analyst Paul Jeng maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price targe
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Erasca (NASDAQ:ERAS) with a Buy and
Bank of America Corp DE increased its stake in shares of Erasca, Inc. (NASDAQ: ERAS) by 89.6% in the
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.14) per share which missed the analyst consens
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PD
New York, New York--(Newsfile Corp. - August 10, 2026) - WHY: Rosen Law Firm, a global investor righ
New York, New York--(Newsfile Corp. - August 10, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nat
LOS ANGELES--(BUSINESS WIRE)---- $ERAS--ERAS Investors Have Opportunity to Lead Erasca, Inc. Securit
NEW YORK--(BUSINESS WIRE)---- $ERAS #ClassAction--Faruqi & Faruqi, LLP, a leading national securitie
SAN FRANCISCO, Aug. 10, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is a
Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- Schall Brown & Schwartz LLP, a national shareholder right
LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action law
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff
Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed
SAN FRANCISCO, Aug. 9, 2026 /PRNewswire/ -- Hagens Berman, a national shareholder rights firm, is ac
New York, New York--(Newsfile Corp. - August 9, 2026) - WHY: Rosen Law Firm, a global investor right
Morgan Stanley analyst Sean Laaman maintains Erasca (NASDAQ:ERAS) with a Equal-Weight and raises
Erasca reported updated Phase 1 ERAS-0015 data, outlined pivotal trial plans and priced an upsized $
B of A Securities analyst Alec Stranahan maintains Erasca (NASDAQ:ERAS) with a Neutral and raises
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discov
At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic canc
Top analysts upgrade MUR, UNH, ESNT, and ERAS stocks. For more rating changes, see analyst ratings p
B of A Securities analyst Alec Stranahan upgrades Erasca (NASDAQ:ERAS) from Underperform to Neutr
Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries,
Mizuho analyst Joseph Catanzaro maintains Erasca (NASDAQ:ERAS) with a Outperform and lowers the p
Erasca (NASDAQ:ERAS) reported quarterly losses of $(0.60) per share which missed the analyst consens
This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecul
US stocks down, NASDAQ falls over 1% on Tuesday. Dow up 0.20%, NASDAQ down 1.24%, S&P 500 down 0
U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate
US stocks mixed with Dow up 150 pts. Dow up 0.27%, NASDAQ down 1.06%, S&P 500 down 0.52%. Energy
Erasca reports early ERAS-0015 data showing tumor response while rejecting Revolution Medicines'
US stock futures mixed, Nasdaq down 1%. Rambus Inc (NASDAQ: RMBS) shares fall 15.1% pre-market after
Shares of Bed Bath & Beyond (BBBY) rose 23.4% in pre-market trading after beating revenue estima
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/
On April 24, 2026, the Company received a letter from legal counsel for Revolution Medicines, Inc. (
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discov
Stifel analyst Laura Prendergast maintains Erasca (NASDAQ:ERAS) with a Buy and raises the price t
On April 21, 2026, Erasca, Inc. (the "Company") narrowed the time period for the anticipated
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen